HIV and hepatitis C virus co-infection (Q35818512)

10 August 2017

1 reference

title

HIV and hepatitis C virus co-infection. (English)

1 reference

10 August 2017

1 reference

1 reference

Jürgen Kurt Rockstroh

series ordinal

1

1 reference

PubMed ID

15219554

10 August 2017

Ulrich Spengler

series ordinal

2

1 reference

PubMed ID

15219554

10 August 2017

language of work or name

1 reference

1 July 2004

1 reference

Lancet Infectious Diseases

10 August 2017

1 reference

10 August 2017

4

1 reference

10 August 2017

7

1 reference

10 August 2017

437-444

1 reference

Trends in diseases reported on U.S. death certificates that mentioned HIV infection, 1987-1999

10 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901059-X

7 January 2021

Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901059-X

7 January 2021

Increasing impact of chronic viral hepatitis on hospital admissions and mortality among HIV-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901059-X

7 January 2021

Mortality for Liver Disease in Patients With HIV Infection: A Cohort Study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901059-X

7 January 2021

Mortality due to hepatitis C-related liver disease in HIV-infected patients in France (Mortavic 2001 study).

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901059-X

7 January 2021

Hepatitis C Virus prevalence among patients infected with Human Immunodeficiency Virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901059-X

7 January 2021

Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901059-X

7 January 2021

Hepatitis C and progression of HIV disease

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901059-X

7 January 2021

Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901059-X

7 January 2021

Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901059-X

7 January 2021

Epidemiology of hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901059-X

7 January 2021

Treatment of acute hepatitis C infection in HIV-infected patients: a retrospective analysis of eleven cases

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901059-X

7 January 2021

Mother-to-infant transmission of hepatitis C virus. Lombardy Study Group on Vertical HCV Transmission

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901059-X

7 January 2021

Management of Hepatitis B and C in HIV Co-Infected Patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901059-X

7 January 2021

High hepatitis C viraemia and impaired antibody response in patients coinfected with HIV.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901059-X

7 January 2021

Virological characteristics of hepatitis C virus infection in HIV-infected individuals with chronic hepatitis C: implications for treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901059-X

7 January 2021

The association between hepatitis C virus genotype and human immunodeficiency virus disease progression in a cohort of hemophilic men.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901059-X

7 January 2021

Hepatitis C virus genotypes and severity of chronic liver disease in haemophiliacs

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901059-X

7 January 2021

Lack of association of hepatitis C virus load and genotype with risk of end-stage liver disease in patients with human immunodeficiency virus coinfection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901059-X

7 January 2021

Progression of chronic hepatitis C to liver fibrosis and cirrhosis in patients coinfected with hepatitis C virus and human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901059-X

7 January 2021

Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901059-X

7 January 2021

Influence of human immunodeficiency virus type 1 infection on the natural course of chronic parenterally acquired hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901059-X

7 January 2021

Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C. UK Haemophilia Centre Directors' Organisation

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901059-X

7 January 2021

Hepatocellular carcinoma in HIV-infected patients with chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901059-X

7 January 2021

Incidence and predictors of severe liver fibrosis in human immunodeficiency virus-infected patients with chronic hepatitis C: a European collaborative study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901059-X

7 January 2021

CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901059-X

7 January 2021

Effect of human immunodeficiency virus infection on hepatitis C virus infection in hemophiliacs

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901059-X

7 January 2021

Hepatitis C and Human Immunodeficiency Virus Envelope Proteins Cooperatively Induce Hepatocytic Apoptosis via an Innocent Bystander Mechanism

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901059-X

7 January 2021

Human immunodeficiency virus facilitates infection/replication of hepatitis C virus in native human macrophages

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901059-X

7 January 2021

Recurrence of hepatitis C virus after loss of virus-specific CD4(+) T-cell response in acute hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901059-X

7 January 2021

Antigen-specific cytokine response to hepatitis C virus core epitopes in HIV/hepatitis C virus-coinfected patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901059-X

7 January 2021

Role of endogenous interferon in hepatitis C virus (HCV) infection and in coinfection by HIV and HCV.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901059-X

7 January 2021

Fibrosing cholestatic hepatitis after liver transplantation in a patient with hepatitis C and HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901059-X

7 January 2021

Rapidly progressive fibrosing cholestatic hepatitis--hepatitis C virus in HIV coinfection.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901059-X

7 January 2021

Factors affecting liver fibrosis in human immunodeficiency virus-and hepatitis C virus-coinfected patients: impact of protease inhibitor therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901059-X

7 January 2021

Differential effect of ritonavir and indinavir on immune response to hepatitis C virus in HIV-1 infected patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901059-X

7 January 2021

Rapidly evolving hepatitis C virus-related cirrhosis in a human immunodeficiency virus-infected patient receiving triple antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901059-X

7 January 2021

Hepatitis C viraemia in HIV-HCV co-infected patients having immune restoration with highly active antiretroviral therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901059-X

7 January 2021

Immune recovery is associated with persistent rise in hepatitis C virus RNA, infrequent liver test flares, and is not impaired by hepatitis C virus in co-infected subjects

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901059-X

7 January 2021

Sustained disappearance of hepatitis C viremia in patients receiving protease inhibitor treatment for human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901059-X

7 January 2021

Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901059-X

7 January 2021

Antiretroviral drug toxicity -- a challenge for the hepatologist?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901059-X

7 January 2021

Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901059-X

7 January 2021

Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901059-X

7 January 2021

Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901059-X

7 January 2021

Drug-induced liver injury associated with the use of nonnucleoside reverse-transcriptase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901059-X

7 January 2021

Hepatotoxicity of nucleoside reverse transcriptase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901059-X

7 January 2021

The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901059-X

7 January 2021

Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901059-X

7 January 2021

Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion: a model of viral-related steatosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901059-X

7 January 2021

Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901059-X

7 January 2021

Hepatitis C virus genotype 3 is cytopathic to hepatocytes: Reversal of hepatic steatosis after sustained therapeutic response

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901059-X

7 January 2021

Liver biopsy is a useful predictor of response to interferon therapy in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901059-X

7 January 2021

Long-term efficacy of combination therapy with interferon-alpha 2b and ribavirin for severe chronic hepatitis C in HIV-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901059-X

7 January 2021

Interferon and ribavirin combination therapy for chronic hepatitis C in human immunodeficiency virus-infected patients with congenital coagulation disorders

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901059-X

7 January 2021

Chronic hepatitis C in HIV infection: feasibility and sustained efficacy of therapy with interferon alfa-2b and tribavirin

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901059-X

7 January 2021

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901059-X

7 January 2021

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901059-X

7 January 2021

Pegylated IFN-alpha2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901059-X

7 January 2021

Pegylated interferon alpha2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901059-X

7 January 2021

Treatment of acute hepatitis C with interferon alfa-2b

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901059-X

7 January 2021

Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901059-X

7 January 2021

Mitochondrial toxic effects and ribavirin

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901059-X

7 January 2021

Care of patients with chronic hepatitis C and HIV co-infection: recommendations from the HIV-HCV International Panel.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901059-X

7 January 2021

Care of patients with hepatitis C and HIV co-infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901059-X

7 January 2021

Liver transplantation in adults coinfected with HIV.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901059-X

7 January 2021

Orthotopic liver transplantation in patients with human immunodeficiency virus and end-stage liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901059-X

7 January 2021

Inhibition of human immunodeficiency virus and growth of infected T cells by the immunosuppressive drugs cyclosporin A and FK 506

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901059-X

7 January 2021

Dose proportional inhibition of HIV-1 replication by mycophenolic acid and synergistic inhibition in combination with abacavir, didanosine, and tenofovir

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901059-X

7 January 2021

The interaction between antiretroviral agents and tacrolimus in liver and kidney transplant patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901059-X

7 January 2021

Interaction between nelfinavir and tacrolimus after orthoptic liver transplantation in a patient coinfected with HIV and hepatitis C virus (HCV).

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901059-X

7 January 2021

Tacrolimus and lopinavir/ritonavir interaction in liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901059-X

7 January 2021

10.1016/S1473-3099(04)01059-X

Identifiers

DOI

1 reference

10 August 2017

1 reference

PubMed ID

15219554